This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Should Value Investors Buy Henry Schein (HSIC) Stock?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Integer Holdings (ITGR) Q4 Earnings Beat Estimates, Margins Up
by Zacks Equity Research
Integer Holdings' (ITGR) fourth-quarter results reflect robust Medical and Non-Medical Sales, besides strength in all the product lines.
PacBio (PACB) Q4 Earnings Match Estimates, Revenues Top
by Zacks Equity Research
Despite robust Consumables revenues, PacBio (PACB) witnesses overall soft performance in the fourth quarter.
Nevro (NVRO) Q4 Earnings Lag Estimates, Revenues Beat
by Zacks Equity Research
Nevro's (NVRO) worldwide revenues improve on a year-over-year basis in Q4, partly owing to robust domestic performance.
Syneos Health (SYNH) Q4 Earnings Beat Estimates, Margins Down
by Zacks Equity Research
Higher reimbursable expenses and growth in Deployment Solutions contribute to Commercial Solutions revenue growth at Syneos Health (SYNH).
Bio-Rad (BIO) Q4 Earnings Miss Estimates, Operating Margin Up
by Zacks Equity Research
Excluding COVID-related sales, Life Science revenues at Bio-Rad (BIO) increase 28.1%, primarily driven by Droplet Digital PCR, process chromatography, Western blotting and qPCR products.
AMN Healthcare (AMN) Q4 Earnings, Revenues Beat Estimates
by Zacks Equity Research
Despite AMN Healthcare's (AMN) robust results in the majority of its segments, it records a soft overall Q4 performance.
How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings
by Zacks Equity Research
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Amedisys (AMED) Q4 Earnings Beat, Operating Margin Dips
by Zacks Equity Research
Amedisys (AMED) delivers strong Home Health performance in the fourth quarter amid cost pressure.
Shockwave Medical's (SWAV) Q4 Earnings Top, Revenues Surge Y/Y
by Zacks Equity Research
Shockwave Medical's (SWAV) fourth-quarter results reflect robust revenue growth and gross margin expansion on the back of strong demand and new launches.
QuidelOrtho (QDEL) Q4 Earnings Top Estimates, Margins Down
by Zacks Equity Research
QuidelOrtho (QDEL) reports robust overall top-line results in fourth-quarter 2022, despite disappointing segmental and geographical performances on a reported basis.
LabCorp (LH) Q4 Earnings Surpass Estimates, Margins Fall
by Zacks Equity Research
The severe foreign exchange headwind, inflationary pressure and the ongoing Ukraine/Russia crisis impact LabCorp's (LH) business performance in Q4.
Henry Schein (HSIC) Q4 Earnings In Line, Gross Margin Up
by Zacks Equity Research
Growth in Technology and Value-added Services and the Medical segment drove Henry Schein's (HSIC) Q4 revenues.
West Pharmaceutical (WST) Q4 Earnings Beat, Order Book Strong
by Zacks Equity Research
West Pharmaceutical's (WST) fourth-quarter results reflect sustained growth in non-COVID-19 demand amid dismal overall performance.
McKesson (MCK) Announces Availability of FDA-Cleared Drug for MCL
by Zacks Equity Research
The availability of the FDA-approved drug via McKesson's (MCK) independent specialty pharmacy is expected to give patients more treatment options for MCL.
Ecolab (ECL) Q4 Earnings & Revenues Beat, Margins Decline
by Zacks Equity Research
Ecolab's (ECL) robust performance across all segments drives its Q4 sales despite business challenges.
PerkinElmer's (PKI) Q4 Earnings Top, Revenues Decline Y/Y
by Zacks Equity Research
PerkinElmer's (PKI) fourth-quarter results benefit from the solid performance of the Discover & Analytics Solutions business, more than offset by lower COVID-related sales.
Is Cardinal Health (CAH) Stock Undervalued Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Zacks Investment Ideas feature highlights: McKesson, Jabil and Halliburton
by Zacks Equity Research
McKesson, Jabil and Halliburton are part of the Zacks Investment Ideas article.
3 Highly-Ranked Stocks that Beat the Market in 2022 to Buy Now
by Benjamin Rains
Digging into three highly-ranked stocks that outperformed the market in 2022 amid the turmoil and are primed to keep running higher in 2023 even if Wall Street is forced to take its foot off the growth pedal.
Bruker (BRKR) Q4 Earnings Beat Estimates, Margins Increase
by Zacks Equity Research
Robust performance across most of the geographies and operating segments drove Bruker's (BRKR) Q4 revenues.
Phibro (PAHC) Q2 Earnings Top Estimates, Gross Margin Up
by Zacks Equity Research
Growing uptake of MFAs, dairy products and vaccines contributed to Phibro's (PAHC) Q2 revenues.
Cardiovascular Systems (CSII) Q2 Earnings, Revenues Miss
by Zacks Equity Research
With the announcement of the merger agreement with Abbott, Cardiovascular Systems (CSII) refrains from providing any update on the 2023 guidance.
DexCom (DXCM) Q4 Earnings Beat Estimates, Volumes Remain Strong
by Zacks Equity Research
DexCom's (DXCM) fourth-quarter results reflect strong domestic and international revenue growth on the back of its real-time Continuous Glucose Monitoring system.
Baxter (BAX) Q4 Earnings Miss Estimates, FY23 Outlook Weak
by Zacks Equity Research
Baxter's (BAX) fourth-quarter results reflect impact of additional sales from the legacy Hilrom's business acquired in 2021. Ongoing macroeconomic challenges hurt earnings significantly.